PPARG and neurodegenerative disease: PPARγ agonists have been shown to be neuroprotective in a number of neurodegenerative diseases (Escribano et al., 2009; Kiaei et al., 2005; Feinstein et al., 2002; Niino et al., 2001) including PD (Dehmer et al., 2004; Breidert et al., 2002; Schintu et al., 2009; Carta et al., 2011).